Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2018

View Archived Issues

Galapagos reports Part 1 interim results from FALCON trial of cystic fibrosis combination treatment

SCHAD role in the regulation of insulin secretion in pathogenic genetic variants and mouse models

A rare mutation in ABCC1 alters APP processing in a familial case of late-onset Alzheimer's disease

SGLT1 variants lower postprandial glucose and may protect from long-term cardiometabolic risk

USP22 controls cell cycle progression in cancer cells through CCND1 deubiquitylation

LCL-161/paclitaxel neoadjuvant trial for triple-negative breast cancers stratified by gene signature

Phase II study of the IGF-1 mimetic BVS-857 for patients with spinal and bulbar muscular atrophy

[18F]T-401, a promising PET tracer for the in vivo quantification of brain MGL occupancy

Inovio presents updated results from HVTN 098 phase I clinical study of PENNVAX-GP

First patient dosed in phase II study of CPC-634 for the treatment of ovarian cancer

Interim analysis results presented from phase IIb EMMINENCE study of MSDC-0602K

Japanese investigators patent new anti-HBV compounds

DAYBREAK phase III study of Lu-AF-35700 does not meet primary endpoint

Aerie Pharmaceuticals patents protein kinase inhibitors

U.S. researchers divulge new SCN9A blockers

Sidecar Therapeutics identifies LOXL2 and MAP3K5 inhibitors

Syndax provides updates on two entinostat trials

SpinalCyte presents 12-month data from phase I/II study of CybroCell in degenerative disc disease

Treatment initiates in first-in-human PIONEER study of GS-030

Alnylam expands Alnylam Act program and provides update on lumasiran studies

Better than Juuling: "Biochemical cigarette" resets metabolism

Fujian Guangshengtang Pharmaceutical cleared to begin clinical trials of GST-HG-161 in China

First patient dosed in MAVA long-term extension study of mavacamten

Ultragenyx to discontinue its Glut1 DS development program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...